232 related articles for article (PubMed ID: 25450879)
1. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Tiseo M; Boni L; Ambrosio F; Camerini A; Vitale MG; Baldini E; Cinieri S; Zanelli F; Defraia E; Passalacqua R; Crino L; Dazzi C; Tibaldi C; Turolla GM; D'Alessandro V; Zilembo N; Riccardi F; Ardizzoni A;
Clin Lung Cancer; 2015 Jan; 16(1):67-70. PubMed ID: 25450879
[TBL] [Abstract][Full Text] [Related]
2. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Tiseo M; Boni L; Ambrosio F; Camerini A; Baldini E; Cinieri S; Brighenti M; Zanelli F; Defraia E; Chiari R; Dazzi C; Tibaldi C; Turolla GM; D'Alessandro V; Zilembo N; Trolese AR; Grossi F; Riccardi F; Ardizzoni A
J Clin Oncol; 2017 Apr; 35(12):1281-1287. PubMed ID: 28135143
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
4. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
6. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
10. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
Ardizzoni A; Favaretto A; Boni L; Baldini E; Castiglioni F; Antonelli P; Pari F; Tibaldi C; Altieri AM; Barbera S; Cacciani G; Raimondi M; Tixi L; Stefani M; Monfardini S; Antilli A; Rosso R; Paccagnella A
J Clin Oncol; 2005 Jan; 23(3):569-75. PubMed ID: 15659503
[TBL] [Abstract][Full Text] [Related]
11. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
14. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
[TBL] [Abstract][Full Text] [Related]
15. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
Dimitroulis J; Rapti A; Stathopoulos GP; Rigatos S; Stathopoulos J; Koutantos J; Athanasiadis A; Tsikritsaki K; Karaindros D; Katis K; Antoniou D; Toumbis M; Giamboudakis P
Oncol Rep; 2008 Oct; 20(4):879-84. PubMed ID: 18813830
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Horn L; Dahlberg SE; Sandler AB; Dowlati A; Moore DF; Murren JR; Schiller JH
J Clin Oncol; 2009 Dec; 27(35):6006-11. PubMed ID: 19826110
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
[TBL] [Abstract][Full Text] [Related]
20. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
